Experience of using a dietary supplement LECITHIN in hospitalized patients.
GE Valendik, SA SHETEKAURI, State Medical Academy, Krasnoyarsk
During the year, more than 80 cardiac patients and the neurological department of academic hospitals in the combined therapy was administered bioadditive (BAA) LECITHIN company ARTLIFE .
All patients were older than 45 years with disease duration more than 5 years. Indications for this purpose were the following: ischemic heart disease, atherosclerosis, hypercholesterolemia, hypertension, obesity. Some patients (32%) had concomitant diseases: heart rhythm disturbances, cholelithiasis, diseases of the gastrointestinal tract. As a control for all patients before treatment and after three weeks of supplementation study was conducted of cholesterol and its fractions. Persons who are elderly or have increased numbers of low-density cholesterol, but a minimum of specific therapy (or diagnoses), while the recommended techniques LECITHIN of 3-4 teaspoons a day for 1 month. In order to control prior to discharge, all patients re-surveyed cholesterol.
During treatment all patients had an objective reduction in cholesterol levels by 2-3 units.
Other drugs that contribute to this process (such as statins), not appointed. During treatment, most patients noted improvement in general condition, increase in activity. Neurological manifestations of a declining asthenoneurotic syndrome, lowering blood pressure, improve sleep.
After being discharged from hospital more than half of patients (50 men) expressed a desire to take LECITHIN outpatients. Two months later, independent of single patients (12 men) were studied cholesterol. Its level remained normal.
The foregoing allows us to broadly recommend supplements ART LIFE lecithin in neurological practice for the treatment and prevention of cerebrovascular disease, especially in the elderly.
The drug is fully compatible with pharmaceuticals, was well tolerated, has a positive effect on the cardiovascular and nervous system, gastro-intestinal tract.
